VAX 102

Drug Profile

VAX 102

Alternative Names: Flagellin.HuM2e; M2e universal influenza vaccine - VaxInnate; M2e-Flagellin; STF2.4xM2e; VAX102

Latest Information Update: 11 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VaxInnate
  • Class Antivirals; Influenza A vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus infections

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I for Influenza-A virus infections (Combination therapy, Prevention, In volunteers) in USA (IM)
  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Influenza-A virus infections (Prevention, In volunteers) in USA (IM & SC)
  • 19 Dec 2011 VaxInnate's recombinant seasonal and pandemic influenza vaccines licensed to CJ CheilJedang Corporation exclusively in South Korea, and non-exclusively in certain South-East Asia countries, excluding China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top